• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Dana Goldman Discusses Determing Value for Breakthrough Therapies

Video

Dana Goldman, PhD, suggests that value for breakthrough therapies is most often associated with health benefits, health economics, and outcomes research; however, there are other sources of value that have not been taken into account yet.

Dana Goldman, PhD, suggests that value for breakthrough therapies is most often associated with health benefits, health economics, and outcomes research; however, there are other sources of value that have not been taken into account yet.

For example, there is value in curing a disease because it not only impacts the patient but also anyone the patient may have come in contact with, including caregivers and family members.

“We need to figure out how all these ancillary sources of value are affected and in particular who should pay for them as well,” Dr Goldman says.

Related Videos
Elena Elimova, MD, associate professor in the Department of Medicine at the University of Toronto and staff medical oncologist at Princess Margaret Hospital
Dr Eric Yang
Adam Brufsky, MD, PhD, University of Pittsburgh
Enrique Velazquez Villarreal, MD, PhD, MPH, MS, assistant professor in the department of integrative translational sciences at City of Hope
Dr Marco Del Riccio
Dr Steven Manobianco
Dr David Kuter
Roy Mathew, MD, screenshot
Dr Marco del Riccio
© 2026 MJH Life Sciences
AJMC®
All rights reserved.